The role of the inflammasome in patients with autoinflammatory diseases

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 1, 2016, Pages 3-14

  Hoffman, Hal M ^a   Broderick, Lori ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Autoinflammation; inflammasome; innate immunity

Indexed keywords

BIOLOGICAL PRODUCT; INFLAMMASOME; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

AUTOINFLAMMATORY DISEASE; BIOLOGICAL THERAPY; FAMILIAL MEDITERRANEAN FEVER; GENETICS; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PAPA SYNDROME; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; ANIMAL; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DRUG DEVELOPMENT; GENETIC PREDISPOSITION; IMMUNOMODULATION; INFLAMMATION; METABOLISM; PHENOTYPE; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DRUG DISCOVERY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLAMMASOMES; INFLAMMATION; MOLECULAR TARGETED THERAPY; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84990874037     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.05.001     Document Type: Review

References (84)

1. 1 Lehman, H.K., Autoimmunity and immune dysregulation in primary immune deficiency disorders. Curr Allergy Asthma Rep, 15, 2015, 53.
2. 2 Ayres, J.S., Inflammasome-microbiota interplay in host physiologies. Cell Host Microbe 14 (2013), 491–497.
3. 3 McGonagle, D., McDermott, M.F., A proposed classification of the immunological diseases. PLoS Med, 3, 2006, e297.
4. 4 Galon, J., Aksentijevich, I., McDermott, M.F., O'Shea, J.J., Kastner, D.L., TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 12 (2000), 479–486.
5. 5 McDermott, M.F., Aksentijevich, I., Galon, J., McDermott, E.M., Ogunkolade, B.W., Centola, M., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97 (1999), 133–144.
6. 6 French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 17 (1997), 25–31.
7. 7 International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90 (1997), 797–807.
8. 8 Aksentijevich, I., Nowak, M., Mallah, M., Chae, J.J., Watford, W.T., Hofmann, S.R., et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46 (2002), 3340–3348.
9. 9 Hoffman, H.M., Wanderer, A.A., Broide, D.H., Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108 (2001), 615–620.
10. 10 Chae, J.J., Cho, Y.H., Lee, G.S., Cheng, J., Liu, P.P., Feigenbaum, L., et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 34 (2011), 755–768.
11. 11 Rosengren, S., Mueller, J.L., Anderson, J.P., Niehaus, B.L., Misaghi, A., Anderson, S., et al. Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia. J Allergy Clin Immunol 119 (2007), 991–996.
12. 12 Nakagawa, K., Gonzalez-Roca, E., Souto, A., Kawai, T., Umebayashi, H., Campistol, J.M., et al. Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Ann Rheum Dis 74 (2015), 603–610.
13. 13 Tanaka, N., Izawa, K., Saito, M.K., Sakuma, M., Oshima, K., Ohara, O., et al. High incidence of NLRP3 somatic mosaicism in chronic infantile neurological cutaneous and articular syndrome patients: the results of an international multicenter collaborative study. Arthritis Rheum 63 (2011), 3625–3632.
14. 14 Zhou, Q., Aksentijevich, I., Wood, G.M., Walts, A.D., Hoffmann, P., Remmers, E.F., et al. Brief report: cryopyrin-associated periodic syndrome caused by a myeloid-restricted somatic NLRP3 mutation. Arthritis Rheumatol 67 (2015), 2482–2486.
15. 15 Federici, S., Calcagno, G., Finetti, M., Gallizzi, R., Meini, A., Vitale, A., et al. Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum Dis 71 (2012), 1961–1965.
16. 16 Rieber, N., Gavrilov, A., Hofer, L., Singh, A., Oz, H., Endres, T., et al. A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants. Clin Immunol 157 (2015), 56–64.
17. 17 Martinon, F., Burns, K., Tschopp, J., The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10 (2002), 417–426.
18. 18 Srinivasula, S.M., Poyet, J.L., Razmara, M., Datta, P., Zhang, Z., Alnemri, E.S., The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 277 (2002), 21119–21122.
19. 19 Bertin, J., DiStefano, P.S., The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ 7 (2000), 1273–1274.
20. 20 Martinon, F., Hofmann, K., Tschopp, J., The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr Biol 11 (2001), R118–R120.
21. 21 Harton, J.A., Linhoff, M.W., Zhang, J., Ting, J.P., Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 169 (2002), 4088–4093.
22. 22 Netea, M.G., van de Veerdonk, F.L., van Deuren, M., van der Meer, J.W., Defects of pattern recognition: primary immunodeficiencies of the innate immune system. Curr Opin Pharmacol 11 (2011), 412–422.
23. 23 Schett, G., Schauer, C., Hoffmann, M., Herrmann, M., Why does the gout attack stop? A roadmap for the immune pathogenesis of gout. RMD Open, 1, 2015, e000046.
24. 24 Franklin, B.S., Bossaller, L., De Nardo, D., Ratter, J.M., Stutz, A., Engels, G., et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol 15 (2014), 727–737.
25. 25 Broderick, L., De Nardo, D., Franklin, B.S., Hoffman, H.M., Latz, E., The inflammasomes and autoinflammatory syndromes. Annu Rev Pathol 10 (2015), 395–424.
26. 26 Fernandes-Alnemri, T., Yu, J.W., Datta, P., Wu, J., Alnemri, E.S., AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458 (2009), 509–513.
27. 27 Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D.R., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458 (2009), 514–518.
28. 28 Xu, H., Yang, J., Gao, W., Li, L., Li, P., Zhang, L., et al. Innate immune sensing of bacterial modifications of Rho GTPases by the pyrin inflammasome. Nature 513 (2014), 237–241.
29. 29 Sutterwala, F.S., Mijares, L.A., Li, L., Ogura, Y., Kazmierczak, B.I., Flavell, R.A., Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med 204 (2007), 3235–3245.
30. 30 Aksentijevich, I., D Putnam, C., Remmers, E.F., Mueller, J.L., Le, J., Kolodner, R.D., et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56 (2007), 1273–1285.
31. 31 de Koning, H.D., van Gijn, M.E., Stoffels, M., Jongekrijg, J., Zeeuwen, P.L., Elferink, M.G., et al. Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol 135 (2015), 561–564.
32. 32 Stack, J.H., Beaumont, K., Larsen, P.D., Straley, K.S., Henkel, G.W., Randle, J.C., et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 175 (2005), 2630–2634.
33. 33 Tassi, S., Carta, S., Delfino, L., Caorsi, R., Martini, A., Gattorno, M., et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1β secretion. Proc Natl Acad Sci U S A 107 (2010), 9789–9794.
34. 34 Brydges, S.D., Mueller, J.L., McGeough, M.D., Pena, C.A., Misaghi, A., Gandhi, C., et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30 (2009), 875–887.
35. 35 Meng, G., Zhang, F., Fuss, I., Kitani, A., Strober, W., A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30 (2009), 860–874.
36. 36 Brydges, S.D., Broderick, L., McGeough, M.D., Pena, C.A., Mueller, J.L., Hoffman, H.M., Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 123 (2013), 4695–4705.
37. 37 Canna, S.W., de Jesus, A.A., Gouni, S., Brooks, S.R., Marrero, B., Liu, Y., et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46 (2014), 1140–1146.
38. 38 Romberg, N., Al Moussawi, K., Nelson-Williams, C., Stiegler, A.L., Loring, E., Choi, M., et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46 (2014), 1135–1139.
39. 39 Kitamura, A., Sasaki, Y., Abe, T., Kano, H., Yasutomo, K., An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med 211 (2014), 2385–2396.
40. 40 Kim, M.L., Chae, J.J., Park, Y.H., De Nardo, D., Stirzaker, R.A., Ko, H.J., et al. Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β. J Exp Med 212 (2015), 927–938.
41. 41 Smith, E.J., Allantaz, F., Bennett, L., Zhang, D., Gao, X., Wood, G., et al. Clinical, molecular, and genetic characteristics of PAPA syndrome: a review. Curr Genomics 11 (2010), 519–527.
42. 42 Braun-Falco, M., Kovnerystyy, O., Lohse, P., Ruzicka, T., Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 66 (2012), 409–415.
43. 43 Holzinger, D., Fassl, S.K., de Jager, W., Lohse, P., Rohrig, U.F., Gattorno, M., et al. Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases. J Allergy Clin Immunol 136 (2015), 1337–1345.
44. 44 Yu, J.W., Fernandes-Alnemri, T., Datta, P., Wu, J., Juliana, C., Solorzano, L., et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 28 (2007), 214–227.
45. 45 Bulua, A.C., Simon, A., Maddipati, R., Pelletier, M., Park, H., Kim, K.Y., et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 208 (2011), 519–533.
46. 46 Simon, A., Park, H., Maddipati, R., Lobito, A.A., Bulua, A.C., Jackson, A.J., et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 107 (2010), 9801–9806.
47. 47 van der Burgh, R., Pervolaraki, K., Turkenburg, M., Waterham, H.R., Frenkel, J., Boes, M., Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. J Biol Chem 289 (2014), 27757–27765.
48. 48 Tricarico, P.M., Kleiner, G., Valencic, E., Campisciano, G., Girardelli, M., Crovella, S., et al. Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds. Int J Mol Sci 15 (2014), 6843–6856.
49. 49 Miceli-Richard, C., Lesage, S., Rybojad, M., Prieur, A.M., Manouvrier-Hanu, S., Hafner, R., et al. CARD15 mutations in Blau syndrome. Nat Genet 29 (2001), 19–20.
50. 50 Liu, Y., Ramot, Y., Torrelo, A., Paller, A.S., Si, N., Babay, S., et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64 (2012), 895–907.
51. 51 Liu, Y., Jesus, A.A., Marrero, B., Yang, D., Ramsey, S.E., Montealegre Sanchez, G.A., et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371 (2014), 507–518.
52. 52 Zhou, Q., Wang, H., Schwartz, D.M., Stoffels, M., Park, Y.H., Zhang, Y., et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 48 (2016), 67–73.
53. 53 Haneklaus, M., O'Neill, L.A., NLRP3 at the interface of metabolism and inflammation. Immunol Rev 265 (2015), 53–62.
54. 54 Wree, A., Broderick, L., Canbay, A., Hoffman, H.M., Feldstein, A.E., From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 10 (2013), 627–636.
55. 55 Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., Tschopp, J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006), 237–241.
56. 56 Cassel, S.L., Eisenbarth, S.C., Iyer, S.S., Sadler, J.J., Colegio, O.R., Tephly, L.A., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 105 (2008), 9035–9040.
57. 57 Duewell, P., Kono, H., Rayner, K.J., Sirois, C.M., Vladimer, G., Bauernfeind, F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
58. 58 Halle, A., Hornung, V., Petzold, G.C., Stewart, C.R., Monks, B.G., Reinheckel, T., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9 (2008), 857–865.
59. 59 Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 11 (2010), 897–904.
60. 60 Dinarello, C.A., Wolff, S.M., Goldfinger, S.E., Dale, D.C., Alling, D.W., Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 291 (1974), 934–937.
61. 61 Goldfinger, S.E., Colchicine for familial Mediterranean fever. N Engl J Med, 287, 1972, 1302.
62. 62 Leung, Y.Y., Yao Hui, L.L., Kraus, V.B., Colchicine—update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 45 (2015), 341–350.
63. 63 Drewe, E., McDermott, E.M., Powell, P.T., Isaacs, J.D., Powell, R.J., Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 42 (2003), 235–239.
64. 64 Nigrovic, P.A., Sundel, R.P., Treatment of TRAPS with etanercept: use in pediatrics. Clin Exp Rheumatol 19 (2001), 484–485.
65. 65 Hawkins, P.N., Lachmann, H.J., McDermott, M.F., Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348 (2003), 2583–2584.
66. 66 Hoffman, H.M., Rosengren, S., Boyle, D.L., Cho, J.Y., Nayar, J., Mueller, J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364 (2004), 1779–1785.
67. 67 Leslie, K.S., Lachmann, H.J., Bruning, E., McGrath, J.A., Bybee, A., Gallimore, J.R., et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 142 (2006), 1591–1597.
68. 68 Ross, J.B., Finlayson, L.A., Klotz, P.J., Langley, R.G., Gaudet, R., Thompson, K., et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 12 (2008), 8–16.
69. 69 Sibley, C.H., Plass, N., Snow, J., Wiggs, E.A., Brewer, C.C., King, K.A., et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64 (2012), 2375–2386.
70. 70 Aksentijevich, I., Masters, S.L., Ferguson, P.J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360 (2009), 2426–2437.
71. 71 Cailliez, M., Garaix, F., Rousset-Rouviere, C., Bruno, D., Kone-Paut, I., Sarles, J., et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis, 29, 2006, 763.
72. 72 Eroglu, F.K., Besbas, N., Topaloglu, R., Ozen, S., Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int 35 (2015), 1733–1737.
73. 73 Grimwood, C., Despert, V., Jeru, I., Hentgen, V., On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology (Oxford) 54 (2015), 1749–1751.
74. 74 Hoffman, H.M., Therapy of autoinflammatory syndromes. J Allergy Clin Immunol 124 (2009), 1129–1140.
75. 75 Hoffman, H.M., Throne, M.L., Amar, N.J., Sebai, M., Kivitz, A.J., Kavanaugh, A., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58 (2008), 2443–2452.
76. 76 Hashkes, P.J., Spalding, S.J., Giannini, E.H., Huang, B., Johnson, A., Park, G., et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 157 (2012), 533–541.
77. 77 Sibley, C.H., Chioato, A., Felix, S., Colin, L., Chakraborty, A., Plass, N., et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis 74 (2015), 1714–1719.
78. 78 Curtis, C.D., Fox, C.C., Treatment of adult hyper-IgD syndrome with canakinumab. J Allergy Clin Immunol Pract 3 (2015), 817–818.
79. 79 La Torre, F., Muratore, M., Vitale, A., Moramarco, F., Quarta, L., Cantarini, L., Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int 35 (2015), 1943–1947.
80. 80 Garcia-Carbonero, R., Carnero, A., Paz-Ares, L., Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14 (2013), e358–e369.
81. 81 Lamkanfi, M., Malireddi, R.K., Kanneganti, T.D., Fungal zymosan and mannan activate the cryopyrin inflammasome. J Biol Chem 284 (2009), 20574–20581.
82. 82 Marchetti, C., Toldo, S., Chojnacki, J., Mezzaroma, E., Liu, K., Salloum, F.N., et al. Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse. J Cardiovasc Pharmacol 66 (2015), 1–8.
83. 83 Coll, R.C., Robertson, A.A., Chae, J.J., Higgins, S.C., Munoz-Planillo, R., Inserra, M.C., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21 (2015), 248–255.
84. 84 Youm, Y.H., Nguyen, K.Y., Grant, R.W., Goldberg, E.L., Bodogai, M., Kim, D., et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21 (2015), 263–269.